Results 291 to 300 of about 988,033 (347)

CVD and mortality outcomes hazard ratios (HRs) by years since quit smoking among former smokers compared with current and never smokers among participants older than 60 years old.

Erfan Tasdighi (9144667), Zhiqi Yao (7123955), Zeina A. Dardari (22640855), Kunal K. Jha (1472410), Ngozi Osuji (11419026), Tanuja Rajan (22640858), Ellen Boakye (12435105), Kunihiro Matsushita (292103), Eleanor M. Simonsick (9025346), Joao A. C. Lima (11194575), Donald M. Lloyd-Jones (9596712), Debbie L. Cohen (12894013), Lawrence J. Appel (7923893), Amit Khera (374933), Michael E. Hall (11268509), Carlos J. Rodriguez (16035283), Suzanne Judd (300944), Shelley A. Cole (7512674), Vasan S. Ramachandran (14600258), Emelia J. Benjamin (7245926), Paulo A. Lotufo (7317083), Marcio Sommer Bittencourt (5085428), Samar R. El Khoudary (10358331), Rebecca C. Thurston (16911868), Carol A. Derby (7026836), Bruce M. Psaty (7634144), Charles B. Eaton (9725876), Michael J. LaMonte (9107478), Peggy M. Cawthon (7918976), Eric S. Orwoll (8806034), Aruni Bhatnagar (338680), Andrew P. DeFilippis (3929621), Michael J. Blaha (8207226)   +32 more
openalex   +1 more source

Relative risk, odds ratio and hazard ratio

The Southwest Respiratory and Critical Care Chronicles
Shengping Yang, Gilbert Berdine
openaire   +1 more source

Performance Characteristics of Anti‐Collagen II Antibodies in Relapsing Polychondritis and Related Diseases: Prospective Analysis, Systematic Review, and Meta‐Analysis

Arthritis Care &Research, Accepted Article.
Background Relapsing polychondritis (RP) is a rare disease defined by recurrent cartilaginous inflammation. Anti‐collagen II (anti‐Col2) antibodies have been proposed as a diagnostic biomarker for RP, but their performance characteristics are not well defined.
Karyssa Stonick, Marcela A. Ferrada, Alice Fike, Kaitlin A. Quinn, Benjamin A. Turturice, Casey Stein, Peter C Grayson   +6 more
wiley   +1 more source

Hazard ratios and their 95% CIs for death from all-causes and specific causes according to the combination of serum albumin and gamma gap levels.

Kenichi Shibuya (830868), Rie Ibusuki (3921539), Daisaku Nishimoto (13021448), Shiroh Tanoue (829573), Chihaya Koriyama (33811), Shuhei Niiyama (11398664), Yasuyuki Kakihana (464608), Toshiro Takezaki (500646), Megumi Hara (692031), Yuichiro Nishida (240029), Sadao Suzuki (173960), Takeshi Nishiyama (173954), Mako Nagayoshi (9180379), Takashi Tamura (33976), Yudai Tamada (17870306), Rieko Okada (786424), Teruhide Koyama (520687), Satomi Tomida (22634045), Kiyonori Kuriki (10221172), Jun Otonari (13021454), Hiroaki Ikezaki (10221160), Asahi Hishida (6090743), Masashi Ishizu (4063306), Sakurako Katsuura-Kamano (468595), Kenji Wakai (174009), Keitaro Matsuo (73893)   +25 more
openalex   +1 more source

Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Belimumab in Pediatric Patients with Systemic Lupus Erythematosus: A Multicenter, Open‐Label Trial

Arthritis Care &Research, Accepted Article.
Objective This study aimed to characterize the pharmacokinetics, pharmacodynamics, safety, and exploratory efficacy of subcutaneous belimumab in pediatric patients with active systemic lupus erythematosus (SLE) receiving standard therapy. Methods This single‐arm, multicenter, open‐label trial (GSK study 200908; NCT04179032) used three‐weight‐band ...
Hermine I. Brunner, Jordi Antón, Inmaculada Calvo‐Penadés, Richard Dimelow, Gerd Horneff, Sylvia Kamphuis, Rebecca Marino, Andre van Maurik, Kirsten Minden, Masaaki Mori, Josephine Ocran‐Appiah, Christel Wilkinson, Yuichi Yamasaki, Deepak Assudani, for the Pediatric Rheumatology Collaborative Study Group (PRCSG) and Paediatric Rheumatology International Trials Organisation (PRINTO) network investigators   +14 more
wiley   +1 more source

Revisiting Hazard Ratios: Can We Define Causal Estimands for Time-Dependent Treatment Effects? [PDF]

Biom J
Edelmann D.
europepmc   +1 more source

β or hazard ratios per 1 standard deviation–increase in eGDR for HVS and major adverse cardiovascular events.

Maojun Liu (5039045), Junyu Pei (6510401), Xinqun Hu (4429330), Xiaopu Wang (1445422)   +3 more
openalex   +1 more source

Role of Prednisone and 25(OH) Vitamin D on Bone Mineral Density and Osteoporosis in Systemic Lupus Erythematosus

Arthritis Care &Research, Accepted Article.
Objective We evaluated the role of 25‐hydroxy vitamin D, prednisone and other risk factors for bone mineral density (BMD) loss and osteoporosis in systemic lupus erythematosus (SLE). Methods We calculated the association between 25‐hydroxy vitamin D [25(OH)D] levels and other potential risk factors with BMD measures (spine T‐scores) and osteoporosis ...
Nima Madanchi, Andrea Fava, Daniel W Goldman, Laurence S Magder, Michelle Petri   +4 more
wiley   +1 more source

Restricted cubic splines show the multivariable adjusted hazard ratio for the risk of vertebral fracture according to the levels of remnant cholesterol (A) and the remnant cholesterol/cholesterol ratio (B).

Changzhi Liu (518454), He Tong (7483838), Xifa Gao (21807611), Jiangchuan Wang (806092), Zicheng Wei (13972869), Yu Wang (12152), Jianhua Wang (159545), Xiao Chen (260187)   +7 more
openalex   +1 more source

Sex differences in medication discontinuation in axial spondyloarthritis.

Arthritis Care &Research, Accepted Article.
Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or Janus kinase inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we ...
Rachael Stovall, Cinthia Blat, Eric Roberts, Jean W. Liew, Katherine Wysham, Namrata Singh, Janna Friedly, Lianne S. Gensler, Gabriela Schmajuk, Jinoos Yazdany   +9 more
wiley   +1 more source